explore -WSS

explore

author：fashion 2025-10-01 14:15:34 - browse：21955

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Living organ donors deserve priority status for transplants

focus

WSS

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Why are elite athletes different? Take a look at their microbes

Can medical device makers keep up in the race to treat obesity?

Biogen nominates mother of director’s child to replace him on board

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Peter Hotez and the public health issue of online harassment

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

As demand for Covid shots wanes, Moderna seeks its next success

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Anesthesiologist group: stop taking Ozempic before surgery

Death of patient in Alzheimer’s trial raises question of possible risks

The high cost of giving birth even with insurance

Bispecific antibodies are next new thing in cancer immunotherapy

Hepatitis C has a cure — but many Americans still lack access to it

Ask STAT: What do you want to know about ChatGPT in medicine?

hotspot

Altering the blood type of lungs raises potential for universal organs for transplants

How to fix the rural physician shortage in the U.S.

WATCH: Why do fingernails fall off when they're damaged?

Paxlovid study fails to answer questions over benefit for broader groups

Why we need to separate burnout from moral injury in health care

Disclosing genetic information: not as worrisome as once feared

focus

focus

hotspot

knowledge